At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 301 enrolled
Drug / intervention
LY3009104 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy
In Brief
A Phase 2 clinical trial evaluating LY3009104, Placebo, and 1 other intervention for Arthritis, Rheumatoid. Completed, enrolled 301 participants across 68 sites in 9 countries.
Detailed Summary
The purpose of this trial is to evaluate the safety and efficacy of LY3009104 in participants with Rheumatoid Arthritis (RA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesCroatia, Czechia, Hungary, India, Mexico, Poland, Romania, Ukraine, United States
CollaboratorsIncyte Corporation
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartOct 2010
Primary CompletionDec 2011
Study CompletionMar 2014
TodayJul 2026
First PostedAug 19, 2010
Enrollment StartOct 1, 2010
Primary CompletionDec 1, 2011
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.9 years ago
Interventions
LY3009104drug
Administered orally
Placebodrug
Administered orally
Methotrexatedrug
Administered orally as background therapy